Related Experiment Videos
The role of lipoprotein[a] in atherosclerosis
1Baylor College of Medicine, The Methodist Hospital, A601, 6565 Fannin Street, Houston, TX 77030, USA. morriset@bcm.tmc.edu
Insights
Lipoprotein (Lp) is a significant risk factor for cardiovascular disease, linked to atherosclerosis and myocardial infarction. While Lp levels correlate with carotid plaques, their direct impact on arterial function requires further investigation.
Area of Science:
- Cardiovascular Research
- Atherosclerosis Pathophysiology
- Lipid Metabolism
Background:
- Lipoprotein (Lp) is recognized as a major risk factor for cardiovascular disease and atherosclerosis.
- Previous studies indicate Lp's involvement in myocardial infarction and ischemic stroke.
- The precise mechanisms by which Lp contributes to arterial disease are still being elucidated.
Purpose of the Study:
- To synthesize recent findings on the role of Lipoprotein (Lp) in atherosclerosis and cardiovascular disease.
- To explore the relationship between Lp levels and arterial structure and function.
- To investigate the molecular interactions of Lp contributing to its atherogenic and thrombogenic properties.
Main Methods:
- Review and synthesis of recent scientific literature on Lipoprotein (Lp).
- Analysis of studies examining Lp levels in relation to cardiovascular events and biomarkers.
- Examination of research investigating Lp's interaction with extracellular matrix and cellular components.
Main Results:
- Lipoprotein (Lp) levels are associated with myocardial infarction, ischemic stroke, and carotid plaques.
- Unlike other lipids, Lp levels do not show a direct correlation with endothelial function or carotid wall thickness.
- Lp enhances low-density lipoprotein (LDL) binding to extracellular matrix (ECM) and may interfere with fibrinolysis.
Conclusions:
- Lipoprotein (Lp) plays a complex role in atherogenesis and thrombosis, distinct from traditional lipid risk factors.
- Further research into Lp's interactions with ECM and fibrinolytic pathways is crucial for understanding its atherogenic potential.
- Understanding Lp's mechanisms may lead to novel therapeutic strategies for cardiovascular disease.
Abstract:
Recent studies confirm and extend previous evidence that lipoprotein (Lp) plays a significant role in atherosclerosis and is one of the top five or six risk factors for cardiovascular disease. In Japanese patients, Lp levels and apo phenotypes are significant predictors for myocardial infarction. Lp levels are significantly higher in ischemic stroke patients than in controls. However, plasma concentrations of Lp are not predictive of ischemic cerebral infarction in either men or women. Serum Lp levels are significantly higher in patients with carotid plaques or measurable intima-media thickness than in controls without. Despite these associations, there is no significant relationship between Lp level and arterial endothelial function, smooth muscle response, or carotid wall thickness, even though other lipid risk factors like low-density lipoprotein cholesterol (LDL-C) and LDL-C/high-density lipoprotein cholesterol (HDL-C) ratio are correlated with abnormal arterial function and structure. There is new evidence that the association of Lp with extracellular matrix (ECM) secreted by arterial smooth muscle cells increases two- to threefold the subsequent specific binding of LDL. Alpha-defensins released from activated or senescent neutrophils stimulate the binding of Lp to ECM of endothelial cells. Several factors that affect the accumulation of Lp and oxidized LDL in the arterial intima have been identified. Several recent studies have provided new insights into the physiologic role that Lp might play in compromising fibrinolysis. The interaction of Lp with cells is clearly distinct from that with ECM and with fibrinogen; the regulation sites within Lp and plasminogen for these regulatory molecules are not identical. These recent advances bring us significantly closer to understanding how Lp exerts its atherogenic and thrombogenic properties.